These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34516322)

  • 1. Cost-utility of azithromycin in patients with severe asthma.
    Buendía JA; Patiño DG; Feliciano-Alfonso JE
    J Asthma; 2022 Oct; 59(10):2008-2015. PubMed ID: 34516322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility of as-needed ICS-formoterol versus to maintenance ICS in mild to moderate persistent asthma.
    Buendía JA; Patiño DG
    BMC Pulm Med; 2021 Dec; 21(1):397. PubMed ID: 34865628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tiotropium for children and adolescents with severe asthma.
    Antonio Buendía J; Patiño DG
    J Asthma; 2023 May; 60(5):1009-1015. PubMed ID: 36047659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma.
    Buendía JA; Patiño DG
    BMC Pulm Med; 2021 Dec; 21(1):398. PubMed ID: 34865635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-utility of tiotropium in patients with severe asthma.
    Buendía JA; Patiño DG
    Cost Eff Resour Alloc; 2024 Jan; 22(1):4. PubMed ID: 38238836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β
    Han S; Kim S; Kim H; Suh HS
    Curr Med Res Opin; 2019 Sep; 35(9):1597-1605. PubMed ID: 30964365
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost‑effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma.
    Buendia JA; Guerrero Patiño D; Cossio-Giraldo YE
    J Asthma; 2022 Oct; 59(10):2016-2023. PubMed ID: 34551659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US.
    Zafari Z; Sadatsafavi M; Mark FitzGerald J;
    Cost Eff Resour Alloc; 2018; 16():3. PubMed ID: 29422778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMART therapy in adolescent and adults patients with moderate persistent asthma: a cost-utility analysis.
    Buendía JA; Patiño DG
    J Asthma; 2022 Dec; 59(12):2367-2374. PubMed ID: 34913809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Utility Analysis of Long-Acting Beta Agonists versus Leukotriene Receptor Antagonists in Older Adults with Persistent Asthma Receiving Concomitant Inhaled Corticosteroid Therapy.
    Altawalbeh SM; Thorpe JM; Thorpe CT; Smith KJ
    Value Health; 2016; 19(5):537-43. PubMed ID: 27565270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of tiotropium in patients with asthma poorly controlled on inhaled glucocorticosteroids and long-acting β-agonists.
    Willson J; Bateman ED; Pavord I; Lloyd A; Krivasi T; Esser D
    Appl Health Econ Health Policy; 2014 Aug; 12(4):447-59. PubMed ID: 24974107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D supplementation for children with mild to moderate asthma: an economic evaluation.
    Antonio Buendía J; Patiño DG; Lindarte EF
    J Asthma; 2023 Sep; 60(9):1668-1676. PubMed ID: 36755388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Utility of Intermittent Inhaled Corticosteroids in Preschoolers with Viral-Triggered Wheeze.
    Buendía JA; Guerrero Patiño D; Giraldo Ramírez JE
    Pediatr Allergy Immunol Pulmonol; 2022 Mar; 35(1):36-42. PubMed ID: 35320007
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-utility of as-needed combination low-dose budesonide-formoterol in adolescents mild asthma.
    Buendía JA; Guerrero Patiño D; Talamoni HL
    Pediatr Pulmonol; 2021 Dec; 56(12):3699-3705. PubMed ID: 34473917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia.
    Antonio Buendía J; Patiño DG
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):575-580. PubMed ID: 34860616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma.
    Zafari Z; Sadatsafavi M; Marra CA; Chen W; FitzGerald JM
    PLoS One; 2016; 11(1):e0146003. PubMed ID: 26751790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost utility of vitamin D supplementation in adults with mild to moderate asthma.
    Antonio Buendía J; Rodriguez-Martinez CE; Sossa-Briceño MP
    J Asthma; 2023 May; 60(5):951-959. PubMed ID: 35920247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial.
    Wilson EC; Price D; Musgrave SD; Sims EJ; Shepstone L; Murdoch J; Mugford HM; Blyth A; Juniper EF; Ayres JG; Wolfe S; Freeman D; Gilbert RF; Hillyer EV; Harvey I
    Pharmacoeconomics; 2010; 28(7):597-608. PubMed ID: 20446755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
    Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
    Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
    Samyshkin Y; Schlunegger M; Haefliger S; Ledderhose S; Radford M
    Int J Chron Obstruct Pulmon Dis; 2013; 8():79-87. PubMed ID: 23386787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.